| |
| |
| Exchange: |
American Stock Exchange |
| Security
Type: |
Common |
| Shares
Out: |
49,160,000 |
| Market
Cap: |
379.52(M) |
| Last
Volume: |
0 |
Avg
Vol: |
0 |
| 52
Week Range: |
$2.14 - $13.81 |
|
| Level
I Sector: |
Financials |
| Level
II Sector: |
Financial Services |
| Level
III Sector: |
Diversified Investments |
|
Member Indexes:
|
Rankings:
|
|
| Insider 3 Months : - |
| Insider 6 Months : - |
| Insider 3/6 Months : - |
|
| Guru Rank Number : - |
| Guru Rank Value : - |
| Guru Occurances : - |
|
|
|
|
|
| |
|
Company Profile Altimmune is a clinical stage biopharmaceutical company focused on developing treatments for obesity and liver diseases. Co.'s primary product candidate, pemvidutide (proposed INN), is a good laboratory practices-1/glucagon dual receptor agonist that is being developed for the treatment of obesity and non-alcoholic steatohepatitis. In addition, Co. is developing HepTcell, an immunotherapeutic agent designed to achieve a functional cure for chronic hepatitis B.
|
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
|
3m +/-:
|
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
|
Actions:
|
|
|
| B |
Buy |
| S |
Sell |
| OE |
Option
Exercised |
| A |
Acquired |
| D |
Disposed |
| AB |
Automatic
Buy |
| AS |
Automatic
Sell |
| IO |
Initial
Ownership |
|
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
| |
| |
Summary (Direct Transactions Only)  |
3 Months |
6 Months |
12 Months |
24 Months |
| Total Shares Bought |
0 |
0 |
300 |
31,500 |
| Total Buy Value |
$0 |
$0 |
$863 |
$138,033 |
| Total People Bought |
0 |
0 |
1 |
3 |
| Total Buy Transactions |
0 |
0 |
1 |
6 |
| Total Shares Sold |
0 |
0 |
0 |
155,302 |
| Total Sell Value |
$0 |
$0 |
$0 |
$2,133,902 |
| Total People Sold |
0 |
0 |
0 |
5 |
| Total Sell Transactions |
0 |
0 |
0 |
9 |
| End Date |
2024-02-08 |
2023-11-07 |
2023-05-09 |
2022-05-09 |
|
| Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
  Drutz David |
Director |
– • – |
2022-01-25 |
4 |
OE |
$2.40 |
$168 |
D/D |
70 |
17,882 |
|
- |
|
| Garg Vipin K |
President and CEO |
• • – |
2021-12-30 |
4 |
D |
$8.93 |
$26,853 |
D/D |
(3,007) |
283,556 |
|
- |
|
| Drutz David |
Director |
– • – |
2021-12-14 |
4 |
OE |
$2.40 |
$334 |
D/D |
139 |
17,812 |
|
- |
|
| Drutz David |
Director |
– • – |
2021-11-19 |
4 |
OE |
$2.40 |
$168 |
D/D |
70 |
17,673 |
|
- |
|
| Garg Vipin K |
President and CEO |
• • – |
2021-09-30 |
4 |
D |
$11.31 |
$34,009 |
D/D |
(3,007) |
292,577 |
|
- |
|
| Garg Vipin K |
President and CEO |
• • – |
2021-08-30 |
4 |
D |
$14.09 |
$42,383 |
D/D |
(3,008) |
295,584 |
|
- |
|
| Roberts M Scot |
Chief Scientific Officer |
• – – |
2021-07-31 |
4 |
A |
$7.71 |
$13,492 |
D/D |
1,750 |
11,611 |
|
- |
|
| Harris Matthew Scott |
Chief Medical Officer |
• – – |
2021-07-31 |
4 |
A |
$7.71 |
$5,589 |
D/D |
725 |
5,762 |
|
- |
|
| Brown William Michael |
Chief Financial Officer |
• – – |
2021-07-31 |
4 |
A |
$7.71 |
$6,191 |
D/D |
803 |
17,721 |
|
- |
|
| Garg Vipin K |
President and CEO |
• • – |
2021-07-30 |
4 |
D |
$9.07 |
$27,273 |
D/D |
(3,007) |
298,592 |
|
- |
|
| Garg Vipin K |
President and CEO |
• • – |
2021-06-30 |
4 |
D |
$9.85 |
$29,619 |
D/D |
(3,007) |
301,599 |
|
- |
|
| Garg Vipin K |
President and CEO |
• • – |
2021-05-30 |
4 |
D |
$12.65 |
$32,599 |
D/D |
(2,577) |
304,606 |
|
- |
|
| Garg Vipin K |
President and CEO |
• • – |
2021-04-30 |
4 |
D |
$14.47 |
$28,926 |
D/D |
(1,999) |
307,183 |
|
- |
|
| Garg Vipin K |
President and CEO |
• • – |
2021-03-30 |
4 |
D |
$13.55 |
$27,073 |
D/D |
(1,998) |
309,182 |
|
- |
|
| Hodges Philip |
Director |
– • – |
2021-03-01 |
4 |
AS |
$16.08 |
$96,480 |
D/D |
(6,000) |
8,731 |
|
-44% |
|
| Garg Vipin K |
President and CEO |
• • – |
2021-02-28 |
4 |
D |
$15.94 |
$31,848 |
D/D |
(1,998) |
311,180 |
|
- |
|
| Shah Nimish P |
10% Owner |
– – • |
2021-02-25 |
4 |
D |
$0.00 |
$0 |
I/I |
(1,000,000) |
3,500,000 |
|
- |
|
| Harris Matthew Scott |
Chief Medical Officer |
• – – |
2021-01-31 |
4 |
A |
$12.14 |
$11,752 |
D/D |
968 |
5,037 |
|
- |
|
| Garg Vipin K |
President and CEO |
• • – |
2021-01-31 |
4 |
A |
$12.14 |
$12,808 |
D/D |
1,055 |
313,178 |
|
- |
|
| Brown William Michael |
Chief Financial Officer |
• – – |
2021-01-31 |
4 |
A |
$12.14 |
$11,375 |
D/D |
937 |
16,918 |
|
- |
|
| Roberts M Scot |
Chief Scientific Officer |
• – – |
2021-01-31 |
4 |
A |
$12.14 |
$5,669 |
D/D |
467 |
9,861 |
|
- |
|
| Garg Vipin K |
President and CEO |
• • – |
2021-01-30 |
4 |
D |
$14.28 |
$33,601 |
D/D |
(2,353) |
312,123 |
|
- |
|
| Schafer Klaus |
Director |
– • – |
2020-12-10 |
4 |
B |
$11.99 |
$23,980 |
D/D |
2,000 |
8,900 |
2.39 |
3% |
|
| Hodges Philip |
Director |
– • – |
2020-12-01 |
4 |
AS |
$13.54 |
$16,614 |
I/I |
(1,227) |
0 |
|
-8% |
|
| Hodges Philip |
Director |
– • – |
2020-11-30 |
4 |
AS |
$12.00 |
$30,000 |
D/D |
(2,500) |
14,731 |
|
3% |
|
417 Records found
|
|
Page 5 of 17 |
|
|
| |
Transaction Code Key: |
Ownership Code Key |
| |
B |
- Buy |
AB |
- Automatic Buy |
D |
- Direct Ownership |
| |
S |
- Sell |
AS |
- Automatic Sell |
I |
- Indirect Ownership |
| |
OE |
- Options Exercised |
A |
- Acquired |
| |
IO |
- Initital Ownership |
D |
- Disposed |
| |
|
|
|
|
|
0.56 (7.82%) 
